Navigation Links
Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
Date:12/20/2010

TARRYTOWN, N.Y., Dec. 20, 2010 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that it will hold a teleconference and webcast at 8:30 a.m. Eastern Time on Monday, December 20, to discuss results of the Phase 3 COPERNICUS study with VEGF Trap-Eye in central retinal vein occlusion (CRVO) and the week 52 follow-up results of the Phase 2 DA VINCI study in patients with diabetic macular edema (DME).  A press release will be issued prior to the call.

Teleconference/Webcast Details To participate in the live call on Monday, December 20, at 8:30 a.m. Eastern Time, please dial (877) 390-5538 for domestic callers and (408) 940-3843 for international callers, participant code 33105543.  The live conference call is being webcast and it can be accessed on the "Newsroom" page of the Company's web site, www.regeneron.com.  The webcast will be available for 30 days following the call.About Regeneron PharmaceuticalsRegeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions.  In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in Phase 3 clinical trials for the potential treatment of gout, diseases of the eye (wet age-related macular degeneration and central retinal vein occlusion), and certain cancers.  Additional therapeutic candidates developed from proprietary Regeneron technologies for creating fully human monoclonal antibodies are in earlier stage development programs in rheumatoid arthritis and other inflammatory conditions, pain, cholesterol reduction, allergic and immune conditions, and cancer.  Additional information about Regeneron and recent news releases are available on Regeneron's web site at www.regeneron.com. Contact Information:Michael Aberman, M.D.

Peter DworkinInvestor Relations

Corporate Communications914.345.7799

914.345.7640michael.aberman@regeneron.com

peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Christine A. Poon Elected to Regeneron Board of Directors
2. Regeneron Announces Presentation at the 2010 Credit Suisse Annual Healthcare Conference
3. Regeneron Announces Presentation at the 17th Annual NewsMakers in the Biotech Industry Conference
4. Regeneron Announces Exercise of Over-Allotment Option and Closing of Underwritten Offering of Common Stock
5. Regeneron Increases Size of Public Offering of Common Stock
6. Regeneron Pharmaceuticals, Inc. Announces The Sale of 4,500,000 Shares of Common Stock
7. Regeneron Announces Panel Discussion at Citis 5th Annual Biotech Day
8. Regeneron Announces Presentation at the UBS Global Life Sciences Conference
9. Regeneron Announces Presentation at the Morgan Stanley Global Healthcare Conference
10. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
11. BioMed Realty Trust Signs New Lease With Regeneron Pharmaceuticals for 131,000 Square Feet at Landmark
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... INDIANAPOLIS , Sept. 9, 2017  Eli Lilly ... key primary and secondary endpoint data for lasmiditan, an ... migraine, which demonstrated statistically significant improvements compared to placebo ... be highlighted today at the 18th Congress of the ... . "The data presented today demonstrate lasmiditan,s ...
(Date:9/7/2017)... , Sept. 7, 2017 NuvoAir (formerly ... Spirometer, announced today a partnership with Novartis Pharma AG to ... NuvoAir,s position as the leading mobile spirometry platform and Novartis, ... ... ...
(Date:9/6/2017)...  Medical professionals are expected to continuously ... their patients. Medical simulations offer clinicians the ... Simulation provides a safe method for teaching ... refine techniques and build confidence, without putting ... such as augmented reality, will now provide ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... ... "Success Files," a short- and long-form documentary style show ... estimated to affect the lives of more than 5 million Americans living with ... voice in the fight for cure and research into the disease, its causes, ...
(Date:9/22/2017)... ... 2017 , ... “Fruit of the Spirit: “Love””: a delightful adventure of ... created. “Fruit of the Spirit: “Love”” is the creation of published author, Halimah Jones, ... of five. Halimah is an avid writer, her inspiration for “Fruit of the Spirit: ...
(Date:9/22/2017)... Diego, CA (PRWEB) , ... September 22, 2017 ... ... offer groceries, wearable, and more products at customers’ doorstep. According to Smart Mart, ... Smart Mart has stated to offer wearable, and customers can find clothing at ...
(Date:9/22/2017)... Greenwich, Connecticut (PRWEB) , ... September 22, 2017 ... ... to conquering Lyme and other tick-borne diseases through research, education and awareness, today ... , A noted immunologist and microbiologist, Dr. Sellati has more than 20 ...
(Date:9/21/2017)... FL (PRWEB) , ... September 21, 2017 , ... 38-Year-Old ... Aesthetic Surgery Center in Naples, Florida is pleased to announce that Plastic Surgeon Kiranjeet ... Top 40 Under 40 is an annual award that was started in ...
Breaking Medicine News(10 mins):